Journal of Cancer Prevention

eISSN 2288-3657
pISSN 2288-3649

Literatures assessing the interaction between calcium and related genetic polymorphisms regarding the risk of colorectal neoplasia (n = 8)

Reference (year)Study designNo. of subjectOutcomeDietDiet-CRC associationGene polymorphismGene-CRC associationGene-diet interaction OR/RR (95% CI)
Ma et al.36 (2001)Nested case-control (population-based, USA)125/318Colorectal cancerCalcium from milkHighest intake of calcium from total milk: RR = 0.66 (0.40–1.09), P = 0.09IGF-I/IGFBP-3IGF-1/IGFBP-3: RR = 1.84 (1.12–3.01), P = 0.01Highest IGF-I/IGFBP-3 molar ratio in nondrinker of low-fat milk: RR = 3.05 (1.29–7.24), P = 0.03; Among men with high IGF-I/IGFBP-3, frequent low-fat milk drinker: RR = 0.40 (0.17–0.87), P = 0.02
Wong et al.29 (2003)Nested case-control (population-based, Singapore)217/890Colorectal and colon cancerCalciumNo associationVDR FokI (rs10735810): FF, Ff, and ffFokI Ff genotype (P = 0.01): OR = 1.51 (1.00–2.29); ff genotype: OR = 1.84 (1.15–2.94) for colorectum FokI Ff genotype (P = 0.01): OR = 1.90 (1.13–3.20); ff genotype: OR = 2.13 (1.19–3.85) for colonThe effect of VDR FokI Ff and ff genotype on risk modified in the presence of lower dietary calcium: OR = 2.10 (1.17–3.78); OR = 2.69 (1.37–5.23), respectively, P = 0.004
Lewis et al.35 (2003)Case-control (clinic-based, USA)161/213Colorectal adenomaCalciumHigher total calcium in controls, P = 0.01CCND1: (GG/AG/AA)CCND1 AA + AG: OR = 1.5 (1.0–2.4), P = 0.18CCND1 GG with high total calcium intake: OR = 0.4 (0.2–0.9)
Peters et al.31 (2004)Nested case-control (population-based, USA)716/729Colorectal adenomaCalciumNot determinedCASR A986S (rs1801725), R990G (rs1042636), Q1011E (rs1801726)CASR genotype: No association CASR diplotype (000/001)a: OR = 0.56 (0.36–0.88)Protective association between calcium intake (1,000 mg/day) and advanced colorectal adenoma stratified by CASR diplotype (000/000), OR = 0.68 (0.47–0.99)
Guerreiro et al.32 (2007)Case-control (population-based, Portugal)196/200Colorectal cancerCalciumHigher intake in controls: P = 0.01Calcium: OR = 0.59 (0.49–0.88), P < 0.05APC D1822V: DD/DV/VVNot determinedHigh calcium intake associated with CRC risk among those carrying DV/VV allele: OR = 0.51 (0.28–0.93)
Dai et al.33 (2007)Case-control (population-based, USA)688 (adenoma) + 210 (hyperplastic polyp)/1,306Colorectal adenoma, hyperplastic polypsCalciumHigher total calcium intake associated with colorectal adenoma: OR = 0.56 (0.45–0.71), P < 0.01; associated with hyperplastic polyps: OR = 0.64 (0.45–0.92), P = 0.01TRPM7 T1482I (rs8042919)TRPM7 T1482I AG/AA: OR = 1.20 (0.94–1.53), P = 0.23 for adenoma; OR = 1.41 (0.99–2.01), P = 0.03 for polypsTRPM7 T1482I with high Ca:Mg intake ratio > 2.78: AG/AA, OR = 1.60 (1.12–2.29), P < 0.01 for adenoma; OR = 1.85 (1.09–3.14), P < 0.01 for polyps
Dong et al.30 (2008)Case-control (population-based, USA)1,600/1,949Colon cancerCalciumHigher dietary intake of calcium in controls;The highest quartile of dietary calcium: OR = 0.72 (0.56–0.91) for proximal; OR = 0.63 (0.49–0.80) for distal cancerCASRIVS3 + 1048 (rs10934578); IVS3-685 (rs12485716); IVS5-90 (rs4678174); IVS6+16 (rs2270916)No association, but stratified by anatomic site (proximal colon): IVS3 + 1048 TT, OR = 1.35 (1.01–1.81), P = 0.09; IVS3-685 AA/AG, OR = 0.84 (0.71–1.00), P = 0.03; IVS5-90 CC/CT, OR = 0.83 (0.70–0.98), P = 0.05; IVS6 + 16CC OR = 0.43 (0.19–0.97), P = 0.04No association
Kim et al.34 (2013)Case-control (clinic-based, Korea)420/815Colorectal cancerCalciumHigher energy-adjusted total calcium intake in controls (P < 0.001)CASR (rs10934578, rs12485716, rs2270916, rs4678174)No associationInteraction between CASR rs2270916 CC and low calcium intake (CC/low): OR = 2.11 (1.27–3.51), P = 0.375;rs10934578GG/low: OR = 1.84 (1.12–3.00), P = 0.295; rs12485716 AA/low: OR = 1.89 (1.14–3.11), P = 0.769; rs4678174 CC/low: OR = 1.73 (1.06–2.83), P = 0.883

CRC, colorectal cancer; RR, relative risk; TRPM7, transient receptor potential cation channel, subfamily M, member 7; CASR, calcium-sensing receptor; APC, adenomatous polyposis coli; CCND1, cyclin D1; IGF-I, insulin-like growth factor 1; IGFBP-3, insulin-like growth factor binding protein 3.

000 = A986, R990, Q1011; 001 = A986, R990, 1011E.

Journal of Cancer Prevention -0001;20:97~105 https://doi.org/10.15430/JCP.2015.20.2.97
© J Cancer Prev
© Korean Society of Cancer Prevention. / Powered by INFOrang Co., Ltd